Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Phase 2a Study of Oral IW-9179 Administered Once Daily for 14 Days to Patients with Functional Dyspepsia

Trial Profile

A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Phase 2a Study of Oral IW-9179 Administered Once Daily for 14 Days to Patients with Functional Dyspepsia

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 22 Oct 2014

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Recanaclotide (Primary)
  • Indications Non-ulcer dyspepsia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Ironwood Pharmaceuticals
  • Most Recent Events

    • 22 Oct 2014 Results presented at the 79th Annual Scientific Meeting of the American College of Gastroenterology.
    • 20 Oct 2014 According to a Ironwood Pharmaceuticals media release, enrollment in this study was limited by stringent inclusion criteria.
    • 18 Mar 2014 Trial status changed to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top